General Information of the Protein
Protein ID
PT00843
Protein Name
Dihydroorotate dehydrogenase (quinone), mitochondrial
Secondarily
Protein Name
Dihydroorotate oxidase
Gene Name
DHODH
Sequence
MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Oxidoreductase
Function
Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. Required for UMP biosynthesis via de novo pathway.
    Show/Hide
Uniprot ID
Primary ID:
Q02127

Secondarily ID:
A8K8C8
Q6P176
    Show/Hide
Ensembl ID
ENSG00000102967
HGNC ID
HGNC:2867
Subcellular Location
Mitochondrion inner membrane
Clinical Information about the Protein
Target 1 ( Dihydroorotate dehydrogenase (DHODH) )
Target Type Successful Target
Disease 4 Target-related Diseases  4
1 Hyperlipidaemia [ICD-11: 5C80]
2 Inflammatory bowel disease [ICD-11: DD72]
3 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y]
4 Myeloid leukaemia [ICD-11: 2B33.1]
Approved Drug(s) 1 Approved Drug  1
1 Teriflunomide
 Drug Info 
Approved
Hyperlipidaemia
Clinical Trial Drug(s) 3 Clinical Trial Drugs  3
1 Vidofludimus
 Drug Info 
Phase 2
Inflammatory bowel disease
2 BREQUINAR
 Drug Info 
Phase 2
Coronavirus Disease 2019 (COVID-19)
3 BAY2402234
 Drug Info 
Phase 1
Myeloid leukaemia
Target 2 ( HUMAN dihydroorotate dehydrogenase (DHODH) )
Target Type Unknown Type Target
Disease 2 Target-related Diseases  2
1 Multiple sclerosis [ICD-11: 8A40]
2 Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 Leflunomide
 Drug Info 
Approved
Multiple sclerosis
2 IMU-838
 Drug Info 
Phase 2/3
Coronavirus Disease 2019 (COVID-19)